{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pyelonephritis-acute/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"d957e39c-6b0e-5ab2-b109-25b3d89f2a69","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field d1fde131-707e-4a4a-8edc-46f014278c5d --><h2>Changes</h2><!-- end field d1fde131-707e-4a4a-8edc-46f014278c5d -->","summary":null,"htmlStringContent":"<!-- begin item f113a071-8dab-4376-9554-1124a4c523b3 --><!-- begin field eda7925a-3784-4a48-bb4c-09bc1cfd93c2 --><p><strong>November 2020</strong> — minor update. Cautions for prescribing ciprofloxacin updated in line with revised manufacturer's SPC. </p><p><strong>August 2020 </strong>— minor update. Broken URL links updated.</p><p><strong>March 2019 </strong>— minor update. Prescribing information for quinolones updated in line with MHRA, 2019, <em>Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">MHRA, 2019</a>].</p><p><strong>January 2019</strong> — minor update. Aortic aneurysm and dissection is now listed as an adverse effect of ciprofloxacin. </p><p><strong>November 2018</strong> — reviewed. A literature search was conducted in November 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. </p><!-- end field eda7925a-3784-4a48-bb4c-09bc1cfd93c2 --><!-- end item f113a071-8dab-4376-9554-1124a4c523b3 -->","topic":{"id":"1ee909c1-6785-5b3a-a71f-c675db878f51","topicId":"44207967-66bd-4750-aa84-8d9a53c85df0","topicName":"Pyelonephritis - acute","slug":"pyelonephritis-acute","lastRevised":"Last revised in November 2020","chapters":[{"id":"02ed8486-e946-512b-82a2-668a9ff16030","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"46426ef8-dbce-5314-8014-895736033f59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0c98a4b-654e-5b3d-acbe-7af83e06b09e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d957e39c-6b0e-5ab2-b109-25b3d89f2a69","slug":"changes","fullItemName":"Changes"},{"id":"ac7d383b-749f-5a71-b1a3-64b8ee85c6e4","slug":"update","fullItemName":"Update"}]},{"id":"d8333a3b-c658-5cb9-8d52-f4731cb7591a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"82a178c6-fb1b-55a0-8fff-db47a9a4e56f","slug":"goals","fullItemName":"Goals"},{"id":"528ddc23-f69e-558e-a643-3efdf3ed0c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"251eeb06-8579-5cc4-8e1a-95f1d66519b7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f66a975d-d6fb-5db8-9b28-8efc292c4f13","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b5e9e7df-f433-574c-9008-725e03502836","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0a10e02-7199-5bc4-858a-f5b264b68ca3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"86ae3b5d-e5ac-595b-9ce2-6bd39b36e14d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"56a59908-ef99-57a5-94c0-91567fd0c3c3","slug":"definition","fullItemName":"Definition"},{"id":"ec53872e-9c88-566c-bda0-5c8be69f09ba","slug":"causes","fullItemName":"Causes"},{"id":"73f19a3b-6441-55c5-81ba-0912f3b42a15","slug":"complications","fullItemName":"Complications"},{"id":"17fd8038-ffd8-57e6-aa5e-f86def547e29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"235cbfdb-ded5-56f1-8b79-6e33631422d9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ca15553-84c0-5297-abd9-5141ab1dbec6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ede39de9-ed86-5d54-8a0d-82bf548356a4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"2c226c8f-c4ef-59ed-828e-590f38c1719c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f5167b2-e2ea-5d21-93ef-3ed426750dea","fullItemName":"Management","slug":"management","subChapters":[{"id":"30a86df1-8159-5bcc-9187-aa647071eeab","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"93430c57-39bc-5b8b-b176-44cccba23928","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"d385ea3c-fa24-5d51-8bf6-b1372c9fdf3c","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f429e0c9-ab9b-5885-b171-ea841f15722e","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"df1e11c6-9e97-5899-b2b9-0eac5877ab4c","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"936e6198-43d8-5e72-be82-c2c59705ea07","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2b045a54-20ef-5b6e-8003-81b3052b42a8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bf21ee38-5a2a-5700-bfd5-24b5084b8cbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4a868f34-40b1-5196-97ec-2b8334024394","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5d08cf27-dc02-5eea-b5c3-b6308f0d1374","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"11dfcefc-cdc3-5c3f-aeea-da5c0be2ebaa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5cc5db18-4c4f-5e6e-9169-72968b0e3705","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f7685686-568f-5174-afd7-a7778a4f2716","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e0c98a4b-654e-5b3d-acbe-7af83e06b09e","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"241115ae-f51e-54ef-ab67-3148befd705f","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 0dbd7496-66fa-40f1-9725-edf98a7df7dd --><h3>Previous changes</h3><!-- end field 0dbd7496-66fa-40f1-9725-edf98a7df7dd -->","summary":null,"htmlStringContent":"<!-- begin item b9aeff0c-f5b4-4e65-9946-469f5d8f6dc6 --><!-- begin field f8155bce-d597-4936-8ef6-590f2093b21f --><p><strong>November 2018</strong> — minor update. Prescribing information updated to be in line with new NICE guidance pyelonephritis (acute): antimicrobial prescribing. </p><p><strong>September 2017 </strong>— minor update. SPC update on quinolones to align all CKS topics prescribing advice. Prostatitis – chronic, Gonorrhoea, Pyelonephritis, Diarrhoea – prevention and advice for travellers, Dyspepsia – unidentified cause, Dyspepsia – proven functional, Dyspepsia – proven peptic ulcer, Diverticular disease, Gastroenteritis and Scrotal pain and swellings. </p><p><strong>December 2016</strong> — minor update. The adverse effects section for ciprofloxacin has been updated to include vision disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2016</a>].</p><p><strong>June 2013 </strong>— reviewed. A literature search was conducted in June 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. No major changes to recommendations have been made.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>October 2008 to March 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>May 2005 </strong>— reviewed. Validated in September 2005 and issued in November 2005.</p><p><strong>December 2001 </strong>— reviewed. Validated in March 2002 and issued in April 2002.</p><p><strong>December 1998 </strong>— written, replacing guidance on <em>Acute pyelonephritis</em>. Validated in March 1999 and issued in May 1999.</p><!-- end field f8155bce-d597-4936-8ef6-590f2093b21f --><!-- end item b9aeff0c-f5b4-4e65-9946-469f5d8f6dc6 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}